PP
ATNM icon

Paloma Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Paloma Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,285
Closed -$102K – 1601
2015
Q2 		$102K Buy
+1,285
New +$110K ﹤0.01% 1676

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Paloma Partners's ATNM Position: Q3 2015 in Review

Paloma Partners sold out of Actinium Pharmaceuticals (ATNM) in Q3 2015, closing a stake of 1,285 shares — an estimated $102K sold.

Paloma Partners first reported a position in ATNM in Q2 2015 and held it in 1 quarter. The position peaked at $102K in Q2 2015. 27 funds tracked by Wall St. Rank hold ATNM as of Q3 2015.

  • Paloma Partners reported no remaining Actinium Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 1,285 Actinium Pharmaceuticals shares in Q3 2015, an estimated $102K.
  • Paloma Partners first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Paloma Partners's Actinium Pharmaceuticals position peaked at $102K in Q2 2015.
  • 27 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.